Inicio › Cáncer del colon y del recto › Massachusetts › Boston
Ensayos clínicos de Cáncer del colon y del recto en Boston, MA
63 estudios para Cáncer del colon y del recto buscan participantes en centros de Boston y alrededores (a unos 30 millas). Abra un estudio para ver quién puede participar y cómo contactar con el equipo.
Texto oficial del estudio (inglés)
A Phase 1 Study Evaluating DISP-10 in Participants With Advanced Gastrointestinal Cancers
ReclutandoFase 1
- Dana-Farber Cancer Institute, Boston
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
ReclutandoFase 1/2
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
ReclutandoFase 2
- Dana-Farber Cancer Institute - Oncology Department, Boston
Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, ERASur Trial
ReclutandoFase 2
- Boston Medical Center, Boston
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
ReclutandoFase 1
- Exelixis Clinical Site #7, Boston
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
ReclutandoFase 1
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Insitute, Boston
The Impact of PReOPerative Exercise and NutritionaL Optimization on Perioperative Outcomes for Patients Undergoing Treatment for Rectal Cancer: The PROPEL Trial
Reclutando
- Dana-Farber Cancer Institute, Boston
- Brigham and Women's Hospital, Boston
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
ReclutandoFase 1/2
- Dana-Farber Cancer Institute, Boston
A Phase 1 Study of IM-1617 in Participants With Advanced Cancer
ReclutandoFase 1
- Massachusetts General Hospital, Boston
A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
ReclutandoFase 1
- Research Site, Boston
- Research Site, Boston
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
ReclutandoFase 3
- Brigham and Women's Hospital (BWH), Boston
- Dana-Farber Cancer Institute (DFCI), Boston
A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer
ReclutandoFase 2
- Dana-Farber Cancer Institute /ID# 270624, Boston
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
ReclutandoFase 1
- Research Site, Boston
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
ReclutandoFase 1/2
- Tufts Medical Center, Boston
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
ReclutandoFase 1
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
ReclutandoFase 1
- Massachusetts General Hospital, Boston
- Beth Israel Deaconess Medical Center, Boston
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
ReclutandoFase 1/2
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
ReclutandoFase 1/2
- Dana Farber Cancer Institute, Boston
A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
ReclutandoFase 1/2
- Massachusetts General Hospital - Main Campus, Boston
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
ReclutandoFase 1
- Dana-Farber Cancer Institute, Boston
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
ReclutandoFase 1/2
- Dana-Farber Cancer Institute, Boston
A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
ReclutandoFase 3
- Massachusetts General Hospital, Boston
- Oncura Health, Boston
Exercise for Gut Microbiome in Patients With Young-Onset Colorectal Cancer Undergoing Chemotherapy: The COURAGE Trial
Reclutando
- Dana Farber Cancer Institute, Boston
Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases
ReclutandoFase 2
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors
ReclutandoFase 1
- Massachusetts General Hospital (MG), Boston
A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
ReclutandoFase 1
- Mass General Cancer Center, Boston
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
ReclutandoFase 1/2
- Dana-Farber Cancer Institute, Boston
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
ReclutandoFase 1
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Collecting Blood and Stool Samples to Detect Colorectal Cancer or Advanced Neoplasia in Lynch Syndrome Patients
ReclutandoEstudio observacional
- Beth Israel Deaconess Medical Center, Boston
- Dana Farber Cancer Institute, Boston
FOG-001 in Locally Advanced or Metastatic Solid Tumors
ReclutandoFase 1/2
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
ReclutandoFase 1/2
- Massachusetts General Hospital Cancer Center, Boston
AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors
ReclutandoFase 1
- Massachusetts General Hospital, Boston
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
ReclutandoFase 1
- Massachusetts General Hospital, Boston
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
ReclutandoFase 1/2
- Massachusetts General Hospital - Dana Farber, Boston
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
ReclutandoFase 1
- Dana Farber Cancer Institute, Boston
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
ReclutandoFase 1
- Beth Israel Deaconess Medical Center, Boston
A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease
ReclutandoFase 2
- Massachusetts General Hospital /ID# 273608, Boston
A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors
ReclutandoFase 1
- Dana-Farber/Massachusetts General Hospital, Inc, Boston
A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
ReclutandoFase 1
- Mass General Brigham Cancer Institute at Massachusetts General Hospital, Boston
A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations
ReclutandoFase 1/2
- Massachusetts General Hospital Cancer Center, Boston
BILe Acid-gut Microbiome Axis MODification Through Diet Education for Colorectal Cancer Prevention
Reclutando
- Massachusetts General Hospital Cancer Center, Boston
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
ReclutandoFase 1
- Research Site, Boston
- Research Site, Boston
LYL273 for Patients With Relapsed or Refractory mCRC
ReclutandoFase 1/2
- Dana-Farber Cancer Institute, Boston
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
ReclutandoFase 1
- Dana-Farber Cancer Institute, Boston
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
ReclutandoFase 1
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
ReclutandoFase 1
- Massachusetts General Hospital, Boston
Video Education With Result Dependent dIsclosure
Reclutando
- Dana Farber Cancer Institute, Boston
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
ReclutandoFase 1/2
- Dana Farber Cancer Institute, Boston
Botensilimab, Balstilimab, and SBRT in Colorectal Cancer
ReclutandoFase 1 temprana
- Massachusetts General Hospital, Boston
COffee and Metabolites Modulating the Gut MicrobiomE in Colorectal caNCER
ReclutandoFase 1/2
- Massachusetts General Hospital, Boston
Remote Monitoring and Symptom Management Digital Application
Reclutando
- Massachusetts General Hospital, Boston
A Study of MGC028 in Participants With Advanced Solid Tumors
ReclutandoFase 1
- Mass General Brigham, Boston
- Dana Farber/Harvard Cancer Center, Boston
A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies
ReclutandoFase 1
- Dana Farber Cancer Institute, Boston
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
ReclutandoFase 1/2
- Massachusetts General Hospital, Boston
This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors
ReclutandoFase 1
- Dana Farber Cancer Institute, Boston
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
ReclutandoFase 1/2
- Massachusetts General Hospital, Boston
A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
ReclutandoFase 1/2
- Dana-Farber Cancer Institute, Boston
Pathways, Risk Factors, and mOleculeS to Prevent Early-onset Colorectal Tumors
ReclutandoFase 1
- Massachusetts General Hospital Cancer Center, Boston
Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years
ReclutandoFase 4
- Massachussets General Hospital, Boston
Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers
ReclutandoFase 1/2
- Massachusetts General Hospital, Boston
Eliminating Barriers to Colorectal Cancer Screening Using Rapid Cycle Testing: A Pilot Study
ReclutandoSe aceptan voluntarios sanos
- Codman Square Health Center, Boston
- East Boston Neighborhood Health Center, East Boston · A 2 mi de distancia
Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
ReclutandoFase 1
- Dana Farber/Partners Cancer Care Inc, Boston
Performance of SGM-101 for the Delineation of Primary and Recurrent Tumor and Metastases in Patients Undergoing Surgery for Colorectal Cancer
ReclutandoFase 3
- Massachusetts General Hospital, Boston
Más información sobre Cáncer del colon y del recto en MedlinePlus
Ensayos de Cáncer del colon y del recto en otras ciudades
- Houston, TX102 estudios
- New York City, NY78 estudios
- Nashville, TN69 estudios
- Los Angeles, CA59 estudios
- Arlington, VA52 estudios
- St. Louis, MO50 estudios
- San Antonio, TX46 estudios
- Philadelphia, PA44 estudios
- Grand Rapids, MI40 estudios
- Baldwin Park, CA37 estudios
- Chicago, IL34 estudios
- Tampa, FL34 estudios
Otros estudios en Boston
- Cáncer de seno112 estudios
- Cáncer de pulmón de células no pequeñas90 estudios
- Cáncer (todos los tipos)85 estudios
- Cáncer metastásico63 estudios
- Cáncer de pulmón62 estudios
- Cáncer de ovario61 estudios
- Cáncer de próstata59 estudios
- Depresión52 estudios
- Cáncer de endometrio50 estudios
- Fallo cardíaco44 estudios
- Leucemia mielógena aguda44 estudios
- Cáncer de páncreas43 estudios
De ClinicalTrials.gov, datos obtenidos el 6 oct 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.